Table 1.

Chronic daily dosing of AZD2171 (3 mg/kg) enhances the response of Calu-6 xenografts to fractionated radiotherapy

TreatmentRTV4 (d)DT (d)Growth delay (d)
Vehicle11 ± 0.55 ± 0.2NA
AZD2171*23 ± 212 ± 212 ± 2
3 × 2 Gy IR
    IR28 ± 29 ± 217 ± 2
    IR + AZD2171 sequential45 ± 517 ± 334 ± 5
    IR + AZD2171 concomitant46 ± 516 ± 135 ± 5
5 × 2 Gy IR
    IR32 ± 28 ± 0.521 ± 2
    IR + AZD2171 sequential48 ± 316 ± 237 ± 3
    IR + AZD2171 concomitant52 ± 617 ± 341 ± 6
  • NOTE: Tumors were treated daily with AZD2171 until the RTV4 was obtained. Growth delay (RTV4treated − RTV4control). Values shown are the mean ± SE.

  • Abbreviations: IR, ionizing radiation; DT, tumor volume doubling time; NA, not applicable.

  • * One tumor treated with chronic 3 mg/kg of AZD2171 regressed.

  • P < 0.001 versus vehicle control; Mann-Whitney U test.

  • P < 0.05 compared with radiation or AZD2171 alone.